Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Single-cell transcriptomic studies reveal altered heterogeneity in CD41 enriched megakaryocytes after targeted therapy in myeloproliferative neoplasm

View Full Paper
Ask AI
Bookmark
Share

Authors

ASA SchildJWJeremy Q. WenJCJohn D. Crispino

Discussion

Loading...

Member takes

Overview

Single-cell analysis reveals targeted therapy shifts megakaryocyte populations and influences hematopoiesis in MPN.

Key Points

  • This research aims to explore the heterogeneity of megakaryocytes in myeloproliferative neoplasms following targeted therapy.
  • Employed single-cell RNA sequencing on enriched megakaryocytes from animal models of MPN.
  • Isolated megakaryocytes from bone marrow by lineage depletion and sorting for CD41+ cells.
  • Analyzed effects of the JAK inhibitor ruxolitinib on megakaryocyte populations.
  • Identified multiple megakaryocyte subpopulations with varying gene expression profiles.
  • Found an 8-fold increase in mature platelet clusters in JAK2V617F mice after targeted therapy.
  • ruxolitinib treatment significantly reduced erythroid-progenitor population and influenced hematopoiesis.

Cite This Study

Schild et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0cehttps://doi.org/10.1182/blood-2025-3764
View Full Paper
Ask AI
Bookmark
Share